The Access to Advanced Health Institute (AAHI) has received $12.7 million to develop a novel immune-stimulating adjuvant formulation, NanoAlum, which aims to improve vaccine protection against complex diseases like tuberculosis and influenza.
The Access to Advanced Health Institute has received an $18 million award from the NIH to develop a temperature-stable, single-dose chikungunya RNA vaccine candidate. The vaccine uses innovative RNA platform technology to protect against the virus, which causes debilitating joint and muscle pain in endemic areas.
A Phase 1 clinical trial of AAHI's thermostable, freeze-dried single-vial ID93 + GLA-SE vaccine candidate showed higher levels of antibodies and favorable cellular immune responses compared to the two-vial presentation. The results represent significant progress in global efforts to combat TB.
AAHI will develop a prototype nasal spray using its novel adjuvant formulation platform, promising to shorten timelines for emergency response to and mitigate impacts from biological threats. The project aims to create a temperature-stable and broadly protective nasal spray against multiple respiratory viruses.
The Access to Advanced Health Institute has received a $9.9 million award to develop an intranasal bivalent influenza RNA vaccine candidate based on its self-amplifying RNA platform that targets both pandemic A(H5N1) and A(H7N9) influenza virus pathogens.
LepVax, IDRI's leprosy vaccine candidate, shows promise in pre-exposure and post-exposure prophylaxis against M. leprae infection in animals. It alleviates and delays neurologic disruptions caused by the bacteria, a major breakthrough for leprosy treatment.
A promising leprosy vaccine candidate, LepVax, is moving into human trials after years of research. The vaccine has been developed using cutting-edge technologies to induce protective responses against the disease.
IDRI's TB Discovery Program will focus on developing more effective, cheaper, and faster-acting drugs to combat multi-drug resistant TB strains. The new funding from Eli Lilly will support the screening of over 500,000 compounds in search of potential TB drugs.
IDRI aims to develop a safe and effective Zika vaccine using RNA-based technology, which can be rapidly manufactured without requiring egg growth or bacteria cultivation. The institute plans to leverage the Zika virus's own machinery for expression of immunogenic proteins.
The Global Health Vaccine Center of Innovation (GHVCI) aims to accelerate vaccine development and make vaccines more accessible globally. The GHVCI combines IDRI's vaccine design technologies with Sanofi Pasteur's expertise in vaccine development, formulation, and production.
A Phase 2a trial will assess the safety and immunogenicity of IDRI's TB vaccine candidate in 60 participants in South Africa, who have previously had active TB. The trial aims to reduce TB recurrence after treatment, a major threat to TB control programs.
IDRI's drug discovery efforts continue with a $3.4 million grant extension from the Bill & Melinda Gates Foundation. The funding supports identifying new leads and drug targets for TB, a devastating disease killing 1.5 million annually.
IDRI's VL vaccine candidate has shown safety and immunogenicity in healthy volunteers, and Zydus' expertise will be crucial in getting the vaccine to those who need it most. The partnership aims to make the vaccine affordable and accessible to all people in need, particularly in endemic countries.
The H5N1 vaccine candidate induced a solid immune response in all three configurations of adjuvant and route of administration, exceeding the CHMP immunogenicity criteria. The results demonstrate the potential for significant 'dose-sparing' with the intradermal delivery device.
IDRI and Medicago present data on their H5N1 Avian Influenza VLP vaccine candidate, combining IDRI's GLA adjuvant with Medicago's proprietary manufacturing technology. The trial shows promising results in evaluating the safety and immunogenicity of the vaccine.
The trial aims to evaluate the safety and immunogenicity of the H5N1 vaccine combined with IDRI's GLA adjuvant, which may result in a self-administered flu vaccine. The collaboration has the potential to expedite vaccination and simplify distribution during a pandemic.
The Infectious Disease Research Institute (IDRI) has received a $1 million grant from RHSC to develop an effective diagnostic tool and vaccine for leprosy. Current approaches are insufficient to eliminate the disease as a public health problem, with 1.6 billion people at risk of exposure.
The first clinical trial of a new vaccine for visceral leishmaniasis has begun, targeting the most deadly form of the disease. The Phase 1 trial will evaluate the safety and immunogenicity of the vaccine in 36 adult volunteers in Washington State and India.